Your browser is no longer supported. Please, upgrade your browser.
Settings
REPL [NASD]
Replimune Group, Inc.
Index- P/E- EPS (ttm)-1.84 Insider Own6.30% Shs Outstand51.91M Perf Week-2.65%
Market Cap1.45B Forward P/E- EPS next Y-2.49 Insider Trans-10.58% Shs Float42.62M Perf Month-7.63%
Income-90.70M PEG- EPS next Q-0.54 Inst Own93.60% Short Float4.88% Perf Quarter-5.40%
Sales- P/S- EPS this Y-13.80% Inst Trans0.22% Short Ratio8.78 Perf Half Y2.06%
Book/sh9.23 P/B3.27 EPS next Y-13.70% ROA-18.70% Target Price- Perf Year-26.41%
Cash/sh9.50 P/C3.17 EPS next 5Y- ROE-20.70% 52W Range27.66 - 54.85 Perf YTD-20.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.03% Beta-
Dividend %- Quick Ratio30.90 Sales past 5Y- Gross Margin- 52W Low9.00% ATR1.41
Employees152 Current Ratio30.90 Sales Q/Q- Oper. Margin- RSI (14)44.72 Volatility4.17% 4.35%
OptionableYes Debt/Eq0.06 EPS Q/Q-19.90% Profit Margin- Rel Volume0.67 Prev Close31.10
ShortableYes LT Debt/Eq0.05 EarningsAug 06 BMO Payout- Avg Volume236.87K Price30.15
Recom1.60 SMA20-2.90% SMA50-3.86% SMA200-12.63% Volume157,712 Change-3.05%
Oct-15-21Resumed BTIG Research Buy $60
Nov-17-20Initiated BTIG Research Buy $60
Nov-02-20Initiated Jefferies Buy $67
Oct-15-20Upgrade H.C. Wainwright Neutral → Buy $25 → $54
Jul-01-20Downgrade H.C. Wainwright Buy → Neutral $25
May-05-20Initiated Barclays Overweight $21
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jul-12-19Upgrade JP Morgan Neutral → Overweight $27 → $26
Jul-08-19Initiated H.C. Wainwright Buy $26
Apr-25-19Initiated Wedbush Outperform $24
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Aug-14-18Initiated Leerink Partners Outperform $25
Aug-14-18Initiated JP Morgan Overweight $26
Oct-01-21 08:01AM  
Aug-09-21 09:52AM  
Aug-06-21 08:00AM  
Aug-02-21 08:00AM  
Jul-07-21 08:00AM  
Jun-03-21 07:00AM  
May-20-21 08:00AM  
May-10-21 08:00AM  
May-05-21 07:00AM  
Apr-28-21 08:00AM  
Apr-21-21 08:00AM  
Apr-12-21 04:01PM  
Mar-17-21 09:15AM  
Mar-11-21 04:01PM  
Mar-04-21 08:00AM  
Feb-18-21 08:00AM  
Feb-09-21 06:39AM  
Feb-04-21 08:00AM  
Jan-11-21 07:00AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Dec-12-20 09:48PM  
Nov-12-20 08:00AM  
Nov-09-20 08:00AM  
Nov-05-20 08:00AM  
Oct-27-20 09:42AM  
Oct-22-20 01:09AM  
Oct-20-20 04:02PM  
04:01PM  
Oct-19-20 04:01PM  
Oct-15-20 11:33AM  
09:51AM  
Oct-14-20 12:29PM  
Aug-07-20 07:00AM  
Aug-04-20 07:00AM  
Jul-22-20 07:00AM  
Jun-22-20 02:27PM  
Jun-17-20 08:00AM  
Jun-11-20 08:47AM  
Jun-08-20 11:21PM  
04:16PM  
Jun-03-20 07:15AM  
07:00AM  
Apr-30-20 06:00AM  
Apr-02-20 07:00AM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-13-20 07:00AM  
Jan-09-20 07:00AM  
Jan-07-20 08:00AM  
Dec-23-19 02:56PM  
Dec-09-19 08:00AM  
Nov-26-19 08:00AM  
Nov-22-19 12:13PM  
Nov-14-19 06:22AM  
Nov-12-19 04:06PM  
Nov-11-19 08:00AM  
Nov-08-19 07:30AM  
Oct-31-19 04:00PM  
02:19PM  
Oct-24-19 08:00AM  
Oct-15-19 07:00AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-13-19 04:39AM  
Aug-14-19 08:00AM  
Aug-06-19 08:00AM  
Jul-19-19 09:16AM  
Jun-28-19 08:00AM  
Jun-01-19 09:00AM  
May-30-19 08:00AM  
May-16-19 07:00AM  
Apr-25-19 02:23PM  
Apr-01-19 07:00AM  
Feb-14-19 08:00AM  
Feb-07-19 08:00AM  
Jan-04-19 12:33PM  
Jan-03-19 08:00AM  
Dec-20-18 08:00AM  
Dec-08-18 06:19PM  
Dec-05-18 08:00AM  
Nov-14-18 08:38AM  
08:00AM  
Sep-26-18 08:00AM  
Sep-06-18 04:01PM  
Aug-30-18 08:00AM  
Aug-14-18 02:49PM  
Jul-24-18 07:44AM  
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Omega Fund IV, L.P.DirectorSep 23Sale33.5812,171408,7024,896,074Sep 27 08:50 PM
Omega Fund IV, L.P.DirectorSep 17Sale33.0294,4633,118,7794,908,245Sep 20 12:53 PM
Omega Fund IV, L.P.DirectorSep 16Sale32.555,537180,2295,002,708Sep 20 12:53 PM
Love ColinChief Operating OfficerSep 15Sale31.2330,000936,900775,809Sep 17 09:11 PM
Love ColinChief Operating OfficerAug 16Sale29.9330,000898,029805,809Aug 18 09:00 PM
Esposito PamelaChief Business OfficerAug 05Option Exercise15.5025,800399,900235,959Aug 06 09:01 PM
Esposito PamelaChief Business OfficerAug 05Sale35.0925,800905,322210,159Aug 06 09:01 PM
Esposito PamelaChief Business OfficerAug 04Option Exercise15.504,20065,100214,359Aug 06 09:01 PM
Esposito PamelaChief Business OfficerAug 04Sale35.004,200147,000210,159Aug 06 09:01 PM
Esposito PamelaChief Business OfficerJul 21Option Exercise1.0112,53812,663222,697Jul 22 09:01 PM
Esposito PamelaChief Business OfficerJul 21Sale33.1712,538415,885210,159Jul 22 09:01 PM
Esposito PamelaChief Business OfficerJul 20Option Exercise1.014,8624,911215,021Jul 22 09:01 PM
Esposito PamelaChief Business OfficerJul 20Sale33.054,862160,689210,159Jul 22 09:01 PM
Esposito PamelaChief Business OfficerJul 15Option Exercise1.014,6004,646214,759Jul 19 09:02 PM
Love ColinChief Operating OfficerJul 15Sale32.0230,000960,600835,809Jul 16 09:03 PM
Esposito PamelaChief Business OfficerJul 15Sale33.374,600153,502210,159Jul 19 09:02 PM
Coffin RobertPresident & Chief R&D OfficerJul 02Sale40.047,810312,7121,775,684Jul 07 09:01 PM
Coffin RobertPresident & Chief R&D OfficerJun 29Sale40.0522,826914,1811,783,494Jun 30 09:00 PM
Coffin RobertPresident & Chief R&D OfficerJun 28Sale40.0414,663587,1071,806,320Jun 30 09:00 PM
Love ColinChief Operating OfficerJun 15Sale34.1030,0001,022,906865,809Jun 16 09:47 PM
Love ColinChief Operating OfficerApr 15Sale30.6330,000918,783895,809Apr 19 06:35 PM
Love ColinChief Operating OfficerMar 15Sale33.5430,0001,006,106886,524Mar 17 09:07 PM
Love ColinChief Operating OfficerFeb 16Sale36.3230,0001,089,537916,524Feb 18 05:58 PM
Omega Fund IV, L.P.10% OwnerFeb 08Sale45.005,249236,2055,141,321Feb 11 11:50 AM
Omega Fund IV, L.P.DirectorJan 26Sale45.4230,3501,378,4445,283,682Jan 28 09:27 AM
Rhodes Jason PDirectorJan 26Sale46.145,558256,446946,000Jan 28 05:08 PM
Omega Fund IV, L.P.DirectorJan 22Sale45.0411,359511,6585,314,032Jan 26 09:56 AM
Coffin RobertPresident & Chief R&D OfficerJan 22Sale44.4360,0002,665,9731,744,118Jan 26 09:00 PM
Esposito PamelaChief Business OfficerJan 19Option Exercise1.015,7275,784181,721Jan 19 09:50 PM
Esposito PamelaChief Business OfficerJan 19Sale42.475,727243,226175,994Jan 19 09:50 PM
Astley-Sparke PhilipChief Executive OfficerJan 19Sale42.478,432358,1171,255,297Jan 19 09:53 PM
Love ColinChief Operating OfficerJan 19Sale42.467,857333,589946,524Jan 19 09:47 PM
Esposito PamelaChief Business OfficerJan 15Option Exercise1.0129,27329,566205,267Jan 19 09:50 PM
Astley-Sparke PhilipChief Executive OfficerJan 15Sale43.4016,568719,0591,263,729Jan 19 09:53 PM
Omega Fund IV, L.P.DirectorJan 15Sale45.191,91686,5845,325,391Jan 19 03:02 PM
Esposito PamelaChief Business OfficerJan 15Sale43.5829,2731,275,717175,994Jan 19 09:50 PM
Love ColinChief Operating OfficerJan 15Sale43.5122,143963,476954,381Jan 19 09:47 PM
Franchi Jean M.Chief Financial OfficerJan 14Option Exercise14.0814,900209,79214,900Jan 15 09:01 PM
Esposito PamelaChief Business OfficerJan 14Option Exercise1.0120,00020,200195,994Jan 19 09:50 PM
Omega Fund IV, L.P.DirectorJan 14Sale45.0917,664796,4705,327,307Jan 19 03:02 PM
Astley-Sparke PhilipChief Executive OfficerJan 14Sale44.4225,0001,110,6141,280,297Jan 19 09:53 PM
Esposito PamelaChief Business OfficerJan 14Sale45.0220,000900,400175,994Jan 19 09:50 PM
Franchi Jean M.Chief Financial OfficerJan 14Sale44.5314,900663,4650Jan 15 09:01 PM
Franchi Jean M.Chief Financial OfficerJan 13Option Exercise14.081001,408100Jan 15 09:01 PM
Franchi Jean M.Chief Financial OfficerJan 13Sale44.191004,4190Jan 15 09:01 PM
Esposito PamelaChief Business OfficerDec 23Option Exercise1.7550,70488,732175,994Dec 28 09:01 PM
Coffin RobertPresident & Chief R&D OfficerDec 22Sale40.04220,0008,808,8001,804,118Dec 28 09:03 PM
Rhodes Jason PDirectorDec 18Sale41.954,319181,18219,285Dec 22 04:38 PM
Rhodes Jason PDirectorDec 17Sale42.0011,535484,47019,550Dec 17 06:21 PM
Rhodes Jason PDirectorDec 16Sale42.1312,675533,99820,247Dec 17 06:21 PM
Rhodes Jason PDirectorDec 15Sale42.4140,8191,731,25321,013Dec 17 06:21 PM
Franchi Jean M.Chief Financial OfficerDec 14Option Exercise14.0825,000352,00025,000Dec 16 09:00 PM
Franchi Jean M.Chief Financial OfficerDec 14Sale43.4525,0001,086,2000Dec 16 09:00 PM
Rhodes Jason PDirectorDec 14Sale43.4937,6591,637,84723,481Dec 14 07:20 PM
Esposito PamelaChief Business OfficerDec 11Option Exercise3.3012,59041,547125,290Dec 15 09:35 PM
Rhodes Jason PDirectorDec 11Sale43.3831,6361,372,51225,757Dec 14 07:20 PM
Rhodes Jason PDirectorDec 10Sale43.1534,3911,484,08327,669Dec 14 07:20 PM
Astley-Sparke PhilipChief Executive OfficerDec 10Sale43.0525,0001,076,1451,305,297Dec 11 09:00 PM
Astley-Sparke PhilipChief Executive OfficerDec 09Sale43.7525,0001,093,7291,330,297Dec 11 09:00 PM
Love ColinChief Operating OfficerDec 09Sale43.7530,0001,312,382976,524Dec 11 09:00 PM
Rhodes Jason PDirectorDec 09Sale43.7741,2161,804,18229,748Dec 09 07:54 PM
SLATTERY JOSEPH PDirectorDec 08Option Exercise3.305,20017,16011,867Dec 09 07:50 PM
SLATTERY JOSEPH PDirectorDec 08Sale46.005,200239,2006,667Dec 09 07:50 PM
Rhodes Jason PDirectorDec 08Sale46.71108,2565,056,59132,234Dec 09 07:54 PM
Dhingra KapilDirectorDec 07Option Exercise1.7540,00070,00040,000Dec 09 07:48 PM
Dhingra KapilDirectorDec 07Sale45.5640,0001,822,3950Dec 09 07:48 PM
Rhodes Jason PDirectorDec 07Sale45.9667,8903,120,45935,709Dec 09 07:54 PM
Love ColinChief Operating OfficerNov 16Sale44.9115,000673,6491,006,524Nov 18 08:00 PM